HOME >> BIOLOGY >> NEWS
From a lowly yeast, researchers divine a clue to human disease

MADISON --Working with a common form of brewer's yeast, University of Wisconsin-Madison researchers have uncovered novel functions of a key protein that allow it to act as a master regulatory switch -- a control that determines gene activity and that, when malfunctioning in humans, may contribute to serious neurological disorders.

The work, published in the Dec. 8 issue of the journal Molecular Cell, shows how a mutation in a single gene can have widespread effects on regulation of the genetic program in a cell, causing some genes to be read more than normal and others less than normal.

While nearly every cell in an organism contains a complete set of DNA, each individual cell uses only a small fraction of that information at any given moment, explains David Brow, the senior author of the new study and a professor of biomolecular chemistry in the UW School of Medicine and Public Health. A host of proteins are responsible for controlling which genetic messages are read and how much of the information is used. Working with yeast, Brow and his colleagues show that a protein called Sen1 plays an important early role in this process.

Mutations in the human version of Sen1 are linked to neurological diseases, including a rare form of amyotrophic lateral sclerosis, also known as ALS or Lou Gehrig's disease, and movement disorders. By exploring how Sen1 works in yeast, Brow provides a powerful tool other researchers can use to better understand the interplay of the protein and gene regulation in human disease.

"This work gives a method to start examining what the defect is in humans," he says.

In the past, says Brow, researchers looked at regulation of individual genes but not the whole genome at once. Using yeast, a small and relatively simple organism, the Wisconsin group developed a method to get a broad view of how Sen1 works and what happens when it doesn't work properly.

Normally, Sen1 acts like a molecular
'"/>

Contact: David Brow
dabrow@wisc.edu
608-262-1475
University of Wisconsin-Madison
7-Dec-2006


Page: 1 2

Related biology news :

1. Human proteins evolving slowly thanks to multitasking genes
2. Tibetan antelope slowly recovering, WCS says
3. Walk slowly for weight loss, according to University of Colorado study
4. Vitamin extends life in yeast, Dartmouth Medical School researchers find
5. Food additive inhibits longevity enzyme in yeast, increases cell toxicity, new study finds
6. Examination of internal wiring of yeast, worm, and fly reveals conserved circuits
7. For yeast, a DNA break ensures sex switch for a grandchild
8. Innovative tagging technique may help researchers better protect fish stocks
9. Penn researchers discover how key protein stops inflammation
10. ASU researchers partner with UOP to make biofuel for military jets a reality
11. Einstein researchers prototype vaccine could provide improved protection against tuberculosis

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: From lowly yeast researchers divine clue human disease

(Date:3/11/2015)... , March 11, 2015   The ... its platform to scientifically measure and harness music ... to real-time biometrics and objective measurements of physiology, ... music at scale in large populations. It is ... technologists and clinicians perform rigorous studies and accelerate ...
(Date:3/10/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ... biometric authentication company focused on the growing mobile ... has been named the "Number One Best Tech ... Rethink Modern ( http://www.rethinkmodern.com/ ) is a web ... and lifestyle that have a unique function or design.  ...
(Date:3/2/2015)... SAN JOSE, Calif. , March 2, 2015 ... ), the leading developer of human interface solutions, ... ID technology that is designed to enable rapid ... Synaptics Natural ID™ module for gaming is a ... and ODMs the ability to quickly integrate fingerprint ...
Breaking Biology News(10 mins):Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 2Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 3NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 3NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 4Synaptics Unveils New Fingerprint ID Solution for Gamers 2Synaptics Unveils New Fingerprint ID Solution for Gamers 3
(Date:3/30/2015)... , March 30, 2015 CASI Pharmaceuticals, Inc. ... the acquisition, development and commercialization of innovative therapeutics addressing ... market with a commercial focus on China ... Drug Administration (CFDA) has approved the Company,s application to ... clear cell carcinoma (OCCC) patients for its proprietary drug ...
(Date:3/30/2015)... GERMANTOWN, Md. , March 30, 2015  /PRNewswire/ ... a leader in synthetic biology, and Merck Serono, ... Germany , today announced an exclusive ... commercialize Chimeric Antigen Receptor T-cell (CAR-T) cancer therapies. ... to develop innovative therapies that modulate the immune ...
(Date:3/30/2015)... Washington, USA (PRWEB) March 29, 2015 ... and the United States and plenary talks by four ... SPIE Optics + Optoelectronics next month in ... technical presentations in 17 conferences alongside a two-day exhibition. ... and photonics , the event will run 13-16 April ...
(Date:3/30/2015)... 2015  Naldemedine, an investigational peripherally acting mu-opioid ... Co., Ltd., met its primary and secondary endpoints ... the treatment of opioid-induced constipation (OIC) in adult ... Study results showed that naldemedine (0.2 mg tablet ... of spontaneous bowel movement (SBM) compared with placebo ...
Breaking Biology Technology:CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 2Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 3Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 4Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 2Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 3Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3
Cached News: